אקופיל 300 מקג0.5 מל ישראל - עברית - Ministry of Health

אקופיל 300 מקג0.5 מל

tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 300 mcg / 0.5 ml - filgrastim

אקופיל 480 מקג0.5 מל ישראל - עברית - Ministry of Health

אקופיל 480 מקג0.5 מל

tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 480 mcg / 0.5 ml - filgrastim

סטימופיל 300 מקג0.5 מל ישראל - עברית - Ministry of Health

סטימופיל 300 מקג0.5 מל

tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 300 mcg / 0.5 ml - filgrastim

סטימופיל 480 מקג0.5 מל ישראל - עברית - Ministry of Health

סטימופיל 480 מקג0.5 מל

tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 480 mcg / 0.5 ml - filgrastim

סטימופג ישראל - עברית - Ministry of Health

סטימופג

tzamal bio-pharma ltd - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml - pegfilgrastim

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 10 מ"ג /מ"ל ישראל - עברית - Ministry of Health

מטוג'קט 10 מ"ג /מ"ל

tzamal bio-pharma ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.